|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2002-12-30
|
|
pubmed:abstractText |
The ninth and tenth FIII domains (FIII9-10) of human fibronectin act in synergy to promote cell adhesion via the interaction with integrin receptors. Here we describe the functional and structural properties of a set of recombinant FIII9-10 mutants containing various alanine substitutions within the key synergistic site, DRVPHSRN in FIII9, either alone or in combination with another substitution (Leu(1408) to Pro), on the opposite face of FIII9, that increases stability and the functional capacity of FIII9-10. We show that the introduction of mutations into the synergistic sequence of FIII9-10 has a negative effect on the adhesion of baby hamster kidney fibroblasts and results in reduced ability of these ligands to recognize integrin alpha(5)beta(1). Conformational stability of the FIII9 domain in the synergy site mutants is likewise reduced in comparison with native FIII9. The Leu(1408) to Pro substitution in mutant FIII9-10 proteins carrying substitutions in the synergy site results in a substantial recovery of the adhesive activity of the mutants and affinity to alpha(5)beta(1). In keeping with the enhancement of functional activity, the Leu(1408) to Pro substitution in the FIII9-10 synergy site mutants also causes a significant increase in conformational stability of FIII9. These observations imply a strong positive correlation between the biological activity and conformational stability of the assessed FIII9-10 mutants and suggest that a Leu(1408) to Pro substitution restores the biological activity of the mutants via their ability to restore their conformational stability. We conclude that domain stability may be a major determinant of the synergistic potential of FIII9. Our data underscore the value of using more than one approach in such structure-function studies and the requirement for validating the global structural integrity of protein ligands in which sequences that disrupt function have been perturbed.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-10444388,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-10592235,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-10769040,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-11331785,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-11500513,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-11884718,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-1385444,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-1423622,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-1725602,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-7511609,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-7538414,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-7545166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-7929152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-8131845,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-8548820,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-9045628,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-9048949,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-9211865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-9245603,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-9533887,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12376529-9949164
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0021-9258
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
278
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
491-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12376529-Animals,
pubmed-meshheading:12376529-Cell Adhesion,
pubmed-meshheading:12376529-Cell Line,
pubmed-meshheading:12376529-Cricetinae,
pubmed-meshheading:12376529-Fibroblasts,
pubmed-meshheading:12376529-Fibronectins,
pubmed-meshheading:12376529-Humans,
pubmed-meshheading:12376529-Integrin alpha5beta1,
pubmed-meshheading:12376529-Ligands,
pubmed-meshheading:12376529-Models, Molecular,
pubmed-meshheading:12376529-Mutation,
pubmed-meshheading:12376529-Protein Binding,
pubmed-meshheading:12376529-Protein Conformation,
pubmed-meshheading:12376529-Protein Denaturation,
pubmed-meshheading:12376529-Recombinant Proteins,
pubmed-meshheading:12376529-Statistics as Topic,
pubmed-meshheading:12376529-Surface Plasmon Resonance,
pubmed-meshheading:12376529-Thermodynamics
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Synergistic activity of the ninth and tenth FIII domains of human fibronectin depends upon structural stability.
|
|
pubmed:affiliation |
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Women's Centre, John Radcliffe Hospital, Headington, Oxford OX3 9DU, United Kingdom.
|
|
pubmed:publicationType |
Journal Article
|
